Get started
Author

Hilary McElwaine-Johnn

Observed names: H. McElwaine-Johnn, H.A. McElwaine-Johnn, Hilary Hilary McElwaine-Johnn, McElwaine-Johnn, Hilary
OpenAlex ID: A5064245797
DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial
2009 · Suzanne Jones, Kirsten Evans, et al. · Vaccine · 139
A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)
2019 · Jean-Pascal Machiels, Ramon Salazar, et al. · Journal for ImmunoTherapy of Cancer · 109
Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid Tumors
2021 · Apostolia M. Tsimberidou, Philip A. Beer, et al. · Clinical Cancer Research · 72
Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K β/δ in relapsed refractory B cell lymphoma
2021 · Loretta J. Nastoupil, Sattva S. Neelapu, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 10
Phase I trial of acoustic cluster therapy (ACT) with chemotherapy in patients with liver metastases of gastrointestinal origin (ACTIVATE study).
2021 · Udai Banerji, Crescens Diane Tiu, et al. · Journal of Clinical Oncology · 10
SPICE, a phase I study of enadenotucirev in combination with nivolumab in tumours of epithelial origin: Analysis of the metastatic colorectal cancer patients in the dose escalation phase
2019 · M.G. Fakih, D. Wang, et al. · Annals of Oncology · 7
2270 Administration of Fedovapagon Causes a Dose-responsive Reduction in Nocturnal Polyuria Index
2013 · Georg Golor, Hilary McElwaine-Johnn, et al. · The Journal of Urology · 6
A phase II study of selective HDAC6 inhibition with KA2507 for second-line treatment of advanced biliary tract cancer (ABC-11).
2020 · John A. Bridgewater, Philip Beer, et al. · Journal of Clinical Oncology · 5
A phase I study of pembrolizumab in combination with enadenotucirev (EnAd) (SPICE) in subjects with metastatic or advanced carcinoma.
2016 · Wael A. Harb, Virginie Cerec, et al. · Journal of Clinical Oncology · 5
Abstract CT151: Phase I study of KA2507, a selective HDAC6 inhibitor, in patients with relapsed or refractory solid tumors
2020 · Apostolia M. Tsimberidou, Philip Beer, et al. · Cancer Research · 3
A phase I study of enadenotucirev (EnAd), an oncolytic Ad11/Ad3 chimeric group B adenovirus, in combination with nivolumab in tumors of epithelial origin.
2017 · Wael A. Harb, Lee S. Rosen, et al. · Journal of Clinical Oncology · 2
A phase I/II study of enadenotucirev, a chimeric Ad11/Ad3 oncolytic group B adenovirus, administered intraperitoneally (IP) in platinum-resistant epithelial ovarian cancer: Pharmacokinetic (PK) and tolerability data from phase I.
2016 · Iain A. McNeish, Agnieszka Michael, et al. · Journal of Clinical Oncology · 2
The Antidiuretic Effect of Fedovapagon can be Effectively Controlled by Dose
2013 · Hilary McElwaine-Johnn, Ralph Schutz, et al. · Neurourology and Urodynamics · 2
Antidiuretic Effect of Fedovapagon in Older Males with Benign Prostatic Hyperplasia and Nocturia
2013 · Hilary McElwaine-Johnn, Georg Golor, et al. · Neurourology and Urodynamics · 2
1529 Novel Non-peptide Pharmacologic Therapy for Nocturia in Men
2010 · Mariam Imnadze, Jeffrey Weiss, et al. · The Journal of Urology · 1
Figures S1 - S6 from Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid Tumors
2023 · Apostolia M. Tsimberidou, Philip A. Beer, et al.
Supplementary Tables S1-S8 from Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid Tumors
2023 · Apostolia M. Tsimberidou, Philip A. Beer, et al.
Data from Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid Tumors
2023 · Apostolia M. Tsimberidou, Philip A. Beer, et al.
Figures S1 - S6 from Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid Tumors
2023 · Apostolia M. Tsimberidou, Philip A. Beer, et al.
92P Characterising the role of HDAC6 in the control of human macrophage IL-10 production
2020 · P.A. Beer, E.A. Bone, et al. · Annals of Oncology
PDF
OCTAVE: A phase I study of enadenotucirev, an oncolytic group B adenovirus, in combination with weekly paclitaxel in platinum-resistant epithelial ovarian cancer
2019 · I.A. McNeish, V. Moreno, et al. · Annals of Oncology
Abstract 1469: Optimizing the tolerability of intravenous oncolytic viral immunotherapy administration: investigation of a low-high-high dose schedule of enadenotucirev (EnAd) administration
2019 · Hilary McElwaine-Johnn, Sam Illingworth, et al. · Cancer Research
Abstract 1469: Optimizing the tolerability of intravenous oncolytic viral immunotherapy administration: investigation of a low-high-high dose schedule of enadenotucirev (EnAd) administration
2019 · Hilary McElwaine-Johnn, Sam Illingworth, et al. · Clinical Research (Excluding Clinical Trials)
A multicenter, open label, first-in-human study of an oncolytic viral vector expressing an agonistic anti-CD40 antibody (NG-350A) in patients with epithelial tumors (FORTITUDE).
2019 · Aung Naing, Ecaterina Elena Ileana Dumbrava, et al. · Journal of Clinical Oncology
Optimizing the tolerability of intravenous oncolytic viral immunotherapy administration: A sub-analysis of tolerability and cytokine data from the EVOLVE study of enadenotucirev (EnAd), an oncolytic adenovirus
2017 · H. McElwaine-Johnn, G. Pover, et al. · Annals of Oncology
Works count: 29
Citation count: 375
H-index: 6
I10-index: 5
Year
Topic
Type